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Abstract
Background: Much of our current knowledge of the molecular expression profile of human
embryonic stem cells (hESCs) is based on transcriptional approaches. These analyses are only partly
predictive of protein expression however, and do not shed light on post-translational regulation,
leaving a large gap in our knowledge of the biology of pluripotent stem cells.
Results: Here we describe the use of two large-scale western blot assays to identify over 600
proteins expressed in undifferentiated hESCs, and highlight over 40 examples of multiple gel
mobility variants, which are suspected protein isoforms and/or post-translational modifications.
Twenty-two phosphorylation events in cell signaling molecules, as well as potential new markers of
undifferentiated hESCs were also identified. We confirmed the expression of a subset of the
identified proteins by immunofluorescence and correlated the expression of transcript and protein
for key molecules in active signaling pathways in hESCs. These analyses also indicated that hESCs
exhibit several features of polarized epithelia, including expression of tight junction proteins.
Conclusion:  Our approach complements proteomic and transcriptional analysis to provide
unique information on human pluripotent stem cells, and is a framework for the continued analyses
of self-renewal.
Background
Human embryonic stem cells (hESCs) are pluripotent
cells isolated from the inner cell mass of the blastocyst [1].
They can be maintained for prolonged periods in culture
and differentiate to representatives of the three germ lay-
ers as well as trophoblasts and germ cells. This differenti-
ation potential may be used to model certain aspects of
human embryogenesis, including the development and
differentiation of pluripotent and other stem cell types
during the processes of gastrulation, neurogenesis and
organogenesis. Thus, hESCs provide a unique and power-
ful system to study otherwise intractable aspects of human
development. Furthermore, these approaches have the
potential to provide differentiated cell types for cell
replacement therapies of degenerative disorders such as
Parkinson's disease and Type I diabetes [2,3]. Before these
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cell therapy applications are developed, an understanding
of the molecular and cellular mechanisms that drive self-
renewal and differentiation is required. Fundamental to
this understanding is the elucidation of the transcriptome
and proteome of hESCs, using approaches that lay a
framework for functional analyses of the unique proper-
ties of these cells.
Large-scale gene expression analyses such as microarray,
massive parallel signature sequencing (MPSS), expressed
sequenced tag (EST) enumeration, and serial analysis of
gene expression (SAGE) have been used to compare mul-
tiple hESC lines [4-7]; hESCs to germ cell tumors [8]; or to
differentiated derivatives in embryoid bodies [9-11] or
neural populations [12]. These approaches have high-
lighted an expanded set of transcripts that mark the
pluripotent state [4,13,14], cross-species commonalities
in the molecular profile of ESCs [6,12,15], prominent
receptors expressed by hESCs [8] and pathways that may
play a role in the regulation of pluripotency [16,17]. Nev-
ertheless, cataloguing the cellular transcriptome is only
predictive of protein expression and typically does not
shed light on post-transcriptional regulation. For exam-
ple, while tens of thousands of transcripts can be followed
simultaneously with SAGE, microarrays and MPSS, these
methods do not routinely detect differences in transcript
splice variants, or polyadenylation status. These differ-
ences may have profound effects on translation, as well as
the isoform and function of the protein produced. Finally,
numerous post-translational modifications are known to
regulate protein function, including enzymatic cleavage,
covalent coupling to other molecules, glycosylation,
phosphorylation and ubiquitination. These issues all
highlight potential shortfalls in our understanding of the
hESC proteome.
Several practical approaches for proteomic analyses are
currently available, the most established of which is the 2-
dimensional (2D) separation of proteins by polyacryla-
mide gel electrophoresis (PAGE). HPLC-tandem mass
spectrometry (HPLC-MS/MS) based technology is rapidly
evolving and has recently been used to detect protein
expression in multiple cell types. An alternate approach is
the recent large-scale adaptation of standard western blot-
ting [18]. In this procedure, a large well is used to separate
the sample by PAGE and lanes are created on the mem-
brane containing immobilized protein with the use of a
manifold. Compatible combinations of primary antibod-
ies are predetermined, with the criterion of being able to
identify proteins that do not co-migrate. Different combi-
nations of primary antibodies are added to each well, with
appropriate dilutions of each primary antibody so that
expressed proteins are detected in a single condition. The
scalability of the system depends on defining suitable
combinations of primary antibodies, with up to 1000
antibodies in 200 lanes being used in the largest screens
thus far. Detection software is used to identify proteins
based on their expected and observed gel mobility. Unlike
2D PAGE and HPLC-MS/MS, large-scale western blotting
only identifies proteins for which antibodies are already
available. While this is not an appropriate screen for iden-
tifying uncharacterized proteins, it greatly simplifies the
verification and functional analyses of proteins that are
detected. In addition, this approach is highly flexible, and
if desired can be focused to particular sets of proteins or
protein function, such as cell signaling molecules. Impor-
tantly, the foundation of this approach is the large
amount of data on individual antibodies, which are
already available and characterized in the literature.
More recently, two research groups have conducted pro-
teomic analyses of hESCs using MS [19-22]. In the present
study, we used two large-scale western blot systems to
examine the expression of > 1000 proteins in hESCs and
detected > 600 proteins that were grouped into 18 func-
tional classes. In addition, we identified 42 examples of
multiple bands for a single protein, likely to be protein
isoforms and/or post-translational modifications, and 22
phosphorylation events in cell signaling molecules. We
correlated the expression of members of key active path-
ways in our transcriptional and proteomic databases and
confirmed the validity of this approach. Using these
approaches we identified new markers for undifferenti-
ated hESCs and highlighted unrecognized epithelial char-
acteristics of hESCs. Our data confirm the importance of
proteomic analyses in complementing transcriptional
profiling and provide a framework for continued analyses
of the molecular and cellular biology of pluirpotent
hESCs.
Results
PowerBlot analysis of hESCs
We first employed a large-scale western blot screen, the
PowerBlot system, to profile protein expression in undif-
ferentiated hESCs. This system used 934 antibodies
toward proteins representing 22 diverse classes of func-
tion, such as transcription factors, the MAP kinase
(MAPK) pathway, and apoptosis, among others. To
expand a large-scale culture of BG01 cells for this assay, a
collagenase- and trypsin- based passaging method was
used [23]. While these conditions have been associated
with the accumulation of trisomies of chromosomes 12,
17 and X [24], the ease of use of these cultures and simi-
larity in gene expression and differentiation potential to
karyotypically normal BG01 hESCs [11,24,25] make them
suitable for such large scale applications. For the Power-
Blot screen, whole cell lysate from BG01 hESCs was sepa-
rated on five 4–15% gradient gels. Each blot contained
size markers and 39 lanes. Each lane was screened with 1–
8 antibodies in combinations that had been predeter-BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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mined to enable accurate identification of well-separated
proteins (Fig. 1A–E). The gels and blots were performed in
duplicate and expressed proteins were identified by their
predicted size and verified by visual inspection.
A total of 545 antibodies detected bands of appropriate
size, which could be compressed to 529 proteins with
unique SwissProt identification numbers (Fig. 1A–E and
Additional File 1). An enlargement of a representative
lane (lane 24 of Blot C) alongside protein markers is
shown in Fig. 1F. Thirteen proteins including AKT,
caveolin1 and ERK1 were detected in multiple lanes using
the same or different antibodies. Information on the anti-
body catalogue number and dilution, band intensity for
each repeat and the averaged value, description of protein
function, and Entrez gene and SwissProt database identi-
fication numbers is shown in Additional File 1. Three
hundred and eighty three antibodies did not detect bands
in this screen, indicating lack of expression, or possibly
technical issues with detection under standard conditions
(Additional File 1).
The size of the detected proteins ranged from 15 kD
(GS15) to 280 kD (ABP-280). The average intensity of the
detected proteins ranged from 195 to 117926 normalized
intensity units (i.u.), with an average of 5367 i.u. The pro-
teins with the highest band intensity were the B2 Bradyki-
nin Receptor (117926 i.u.), Karyopherin α (80698 i.u.),
and BiP (74922 i.u.), whilst the proteins with the lowest
intensity that could be verified by visual inspection were
Inhibitor 2 (247 i.u.), Caspase 8 (201 i.u.), and OXA1Hs
(195 i.u.). Finally, the consistency of this assay was dem-
PowerBlot analysis of undifferentiated BG01 hESCs Figure 1
PowerBlot analysis of undifferentiated BG01 hESCs. This large-scale western blot consisted of five gels run in duplicate 
and probed with 934 antibodies. (A-E) One set of blots is shown at a contrast that highlights most bands. (F) A representative 
lane (gel C, lane 24) aligned with protein markers used for band identification. (G) Scatter-plot of the normalized average inten-
sity (i.u.) values for each protein indicating a linear relationship between duplicate blots. Datasets for this analysis are in Addi-
tional Tables 1 and 2.BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
Page 4 of 16
(page number not for citation purposes)
onstrated by plotting the normalized average intensity
values for each protein, which revealed a linear relation-
ship between the duplicate samples (Fig. 1G).
Kinexus analysis of hESCs
A more focused screen was used to profile expression of
protein kinases, phosphatases and phosphorylated sites
in cell signaling molecules in hESCs. The Kinexus assays
contained 140 antibodies to these related classes of pro-
teins and phospho-sites. Karyotypically normal BG03
hESCs grown on a fibronectin matrix in MEF-CM [26]
were used for this analysis, and whole cell lysate was sep-
arated on four 12.5% gels for western blotting. Eighty five
immunoreactive bands were identified, representing 38
protein kinases and 16 phosphatases, their isoforms, and
22 phosphorylated sites in signaling molecules (Fig. 2A–
D, Additional File 1). Sixty-four antibodies did not detect
their corresponding antigen (Additional File 1).
Functional classification of proteins expressed in hESCs
The PowerBlot and Kinexus assays identified a diverse
range of proteins expressed in hESCs. To further annotate
these data, the detected proteins were ordered into 18 sub-
groups based on protein function (Additional File 2). For
example, 16 factors with known or implied roles in the
regulation of self-renewal or pluripotency of mESCs or
hESCs, such as Oct4 [27], STAT3 [28], members of the
FGF [29], PI3 kinase [30], Src [31] or MAPK pathways
[32], and phosphorylated isoforms of GSK3, STAT3 and
p38 MAPK, were grouped under "Pluripotency" (Fig. 3A
and Additional File 2). Another functional group (Cell
surface) consisted of 20 transmembrane or cell surface
proteins (Additional File 2). This included several recep-
tors for peptides and growth factors, such as neurotensin
receptor 3, the B2 bradykinin, endothelin 1, and
thrombin receptors, and the glial derived neurotrophic
factor receptor α (Fig. 3B). These molecules may be useful
Kinexus blots of undifferentiated BG03 cells Figure 2
Kinexus blots of undifferentiated BG03 cells. Four blots were used to probe BG03 lysate with (A, B) 76 antibodies for 
protein kinases, (C) 27 antibodies for phosphatases and (D) 37 antibodies for phosphoylated sites in cell signaling molecules. 
Identified bands are indicated (*). Datasets for this analysis are in Additional Tables 1 and 2.BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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Functional classification and mobility variants of proteins detected in hESCs Figure 3
Functional classification and mobility variants of proteins detected in hESCs. (A) Proteins with known or suggested 
roles in self-renewal are shown, including Oct4, STAT3, Smad2/3 and FGF2 (Additional Table 2, "Pluripotency"). Isoforms of 
FGF2, and phospho-GSK3 are indicated (*). (B) Cell surface proteins are shown, including Connexin 43, E-Cad and GDNFRα 
(Additional Table 2, "Cell Surface"). Other functional classes of proteins are indicated in Additional Table 2. (C) A total of 42 
proteins, including FGF2, HSP70 and ERK1, were found to have multiple bands in either the PowerBlot or Kinexus blots. These 
bands migrated closely but were sufficiently separated from other detected proteins. Bands predicted to be isoforms of the 
indicated protein are highlighted in some panels (*).BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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as targets for cell sorting experiments, and expression of
these receptors could identify bioactive peptides or
growth factors that may influence hESC self-renewal or
differentiation.
Other functional classification of the proteins detected by
the PowerBlot screen included: transcription factors (71
proteins), nucleus and nuclear transport (144), cytoskele-
ton (75), cell adhesion (45), MAP kinase pathway (24),
protein kinase A (13), protein kinase C (20), tyrosine
kinases (15), adaptors and tyrosine kinase substrates (51),
protein phosphatases (17), GTPases and regulators (42),
calcium signaling (23), cell cycle (87), apoptosis (61),
membrane research (62), and other functions (51) (Addi-
tional File 1). Some proteins were included in multiple
functional categories due to overlapping properties, such
as AIM-1, which was included in the cell cycle as well as in
the nucleus/nuclear transport categories. The Kinexus
expression data was organized separately into cell signal-
ing-related functional groups (Additional File 1). In addi-
tion, 35 proteins were detected by both the PowerBlot and
Kinexus systems (Table 1).
Detection of protein isoforms or post-translational 
variants
Unlike many cDNA-based gene expression assays, western
blotting has the capacity to detect multiple protein iso-
forms due to translation of different mRNA splice vari-
ants, as well as post-translational modifications such as
enzymatic cleavage, glycosylation, or phosphorylation.
Examination of the blots described here identified 42
examples of multiple banding for a single target antigen
(Fig. 3C). These candidates exhibited closely migrating
multiple bands, which were close to their predicted size
but were sufficiently separated from other proteins. For
example, four closely migrating bands were observed for
FGF2 (Fig. 3C, top panel), which may represent known
glycosylation variants of this growth factor [33]. Other
known examples of post-translational modifications
included those of HSP70, IKKgamma and ERK1.
Verification of protein expression by 
immunocytochemistry
The PowerBlot and Kinexus assays identified proteins
based on their expected and observed molecular weight,
using combinations of antibodies that had been predeter-
mined to detect proteins of sufficiently different sizes.
Proteins known to be expressed by hESCs and also identi-
fied by these assays, included Oct4, E-CAD, Connexin 43
and Hsp70. To verify expression using a complementary
approach, we performed immunoflurorescent staining for
10 proteins not previously reported to be expressed in
hESCs by immunocytochemistry, using karyotypically
normal BG01 cultures (Fig. 4A–K). These included ABP-
280, a homodimeric actin-binding protein often associ-
ated with membrane glycoproteins; CtBP1 and CtBP2,
two C terminal binding proteins that are a class of tran-
scription corepressors; GS-28, a golgi protein; HDJ-2, a
member of the DnaJ-related Hsp40 (heat shock protein
40) subfamily; L-Caldesmon, a cytoplasmic actin-binding
protein; Rabaptin, a GTP-binding protein; phosphor-
ylated-p130 Cas, a docking protein with an amino-termi-
nal SH3 domain that may function as a molecular switch
that regulates CAS (Crk-associated substrate) tyrosine
phosphorylation; Ras-GAP and phosphorylated Ras-GAP
(p-Y460), a protein that down-regulates the signal trans-
ducer p21ras; and ShcC, a protein with an N-terminal
phosphotyrosine-binding domain. These proteins were
Table 1: Proteins detected by both PowerBlot and Kinexus systems
Protein name Swiss Nr Protein name Swiss Nr
BMX P51813 MEK2 P36506
CaM Kinase Kinase Q64572 MKP2 Q62767
Casein Kinase I epsilon P49674 p38 alpha/SAPK2a Q16539
Casein Kinase II alpha/CK2a P19139 Paxillin P49024
Cdk1/Cdc2 P06493 PKA C P17612
Cdk5 Q00535 PKC beta P05771
Cdk7 P50613 PKC delta Q05655
DAP Kinase P53355 PP2A Catalytic alpha P05323
DAP3 P51398 PP5/PPT P53042
ERK1 Q63538 PTP1B P18031
ERK2 P27703 PTP1C/SHP1 P29350
FAK Q00944 PTP1D/SHP2 Q06124
GSK-3 beta P18266 Rb P13405
I kappa B alpha P25963 Rsk Q15418
IKK beta O14920 Stat1 A46159
JAK1 P23458 Stat3 P52631
JNK1 P45983 VHR P51452
MEK1 Q02750BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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Verification of protein expression using immunocytochemistry Figure 4
Verification of protein expression using immunocytochemistry. (A-K) Ten proteins that were detected in undifferen-
tiated hESCs by western blotting were also detected by immunofluorescence of BG01 cells grown in MEF-CM. Ras-GAP 
(pY460) is a phosphorylated form of Ras-GAP. The same antibodies were used in this analysis as in the PowerBlot assay, 
except phospho-p130 Cas (Tyr165). (L) Oct4 was used as a positive control. (M-R) Oct4, TNIK and p130 Cas as markers of 
undifferentiated hESCs. BG01 cultures were partially differentiated by exposure to 10% fetal bovine serum for 3 days. (M) 
Oct4 was expressed uniformly in undifferentiated cells, (P) but was downregulated in morphologically differentiated areas after 
3 days in serum (arrowhead). (N) TNIK expression was localized to the cytoplasm, and (N, Q) expression appeared to be 
restricted to morphologically undifferentiated cells (arrowhead). (O) p130 Cas was detected in a membrane/peripheral-cyto-
plasmic pattern in undifferentiated cells, (R) but this distribution was substantially altered in differentiating cells with a flattened 
morphology, which exhibited a general cytoplasmic, or perinuclear profile. Scale bar for A-L: (A, L) 200 μm; (C, D, F, H, I, J, K) 
100 μm; (B, E, G) 50 μm. Scale bar for M-R: (M, N, P, Q): 100 μm ; (O, R): 50 μm.BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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all expressed by hESCs, with the expected subcellular
localization (Fig. 4A–K). Oct4 was used as a positive con-
trol (Fig. 4L). These results suggested that most of the
bands in the PowerBlot and Kinexus assays were likely to
be correctly identified.
Preliminary analyses also indicated that expression of
some of these proteins was downregulated in differenti-
ated cells, including p130 Cas and the Traf2- and Nck-
interacting kinase (TNIK). TNIK is known to be involved
in the inhibition of cell spreading via disruption of F-actin
[34,35]. Immunofluorescence was used to examine the
expression of TNIK and p130 Cas during early differentia-
tion of hESCs. BG01 cultures were partially differentiated
by growth in serum containing media for 3 days. This con-
dition generated heterogeneous populations containing
Oct4+ cells with characteristic hESC morphology and less
tightly packed, and morphologically differentiated areas,
lacking expression of Oct4 (Fig 4M, P). TNIK was
expressed highly in undifferentiated hESCs, and in the
undifferentiated areas at day 3, but was downregulated in
areas undergoing morphological differentiation (Fig 4N,
Q). This may indicate that TNIK is active in hESCs and
degraded rapidly upon differentiation. p130 Cas was
detected in a membrane/peripheral-cytoplasmic pattern
in hESCs (Fig 4O). The distribution of p130Cas was sub-
stantially altered in differentiating cells with a flattened
morphology, exhibiting a general cytoplasmic, or perinu-
clear profile (Fig 4R). This could indicate an alteration in
the function of p130 Cas as pluripotent cells differentiate.
These analyses suggested that the change in expression or
distribution of these proteins could be used as markers for
undifferentiated hESCs.
Comparison of proteomic and transcriptional profiles of 
hESCs
We have previously employed the Illumina Bead Array
system for the large-scale profiling of gene expression in
hESCs using 24,000 transcript probes [11]. To compare
proteomic and transcriptional analyses of hESCs, the lev-
els of > 600 proteins detected using large scale blotting
were correlated with the levels of transcripts detected with
the Illumina platform (Additional File 3). In general, a
close match between the expression level of transcript and
protein was observed: transcripts for nearly all the
detected proteins were also identified in the Illumina
analysis, and most proteins expressed at high levels also
exhibited high mRNA levels.
We reasoned that a focused comparison of specific signal-
ing pathways using a combination of proteomic and tran-
scriptional data was likely to be much more informative
than a global interrogation of hESCs. Several major signal
pathways that have been suggested to be involved in self-
renewal were examined to test this approach. These
included the FGF, TGFβ, GSK3β/Wnt/β-catenin and Jak/
Stat pathways [17,29,36-39], as well as the more recently
suggested MAPK/ERK and Gap junction pathways
[32,40]. Correlating transcriptional and proteomic data
provided direct confirmation that these pathways were
present and likely functional in hESCs (Table 2). For
example, FGF2 protein was expressed highly in hESCs and
expression of key members of the TGFβ, Wnt, Jak/Stat and
Gap junction pathways, namely Stat1, SMADs, GSK3β, β-
catenin and Connexin 43, were detected in both transcrip-
tional and proteomic databases.
This independent confirmation of known networks led us
to examine other pathways that showed a similar correla-
tion but have not been identified as key regulators of
either self-renewal or differentiation, or suggest unappre-
ciated characteristics of hESCs. Four signaling pathways
(IGF, ERBB2, GPCR, and GDNF) and the tight junction
complex were highlighted by this analysis (Table 2), and
expression of key proteins in these pathways was con-
firmed. A detailed study demonstrating the importance of
the IGF and ERBB2 pathways in hESC self-renewal has
been performed and enabled the development of a
defined medium for hESC maintenance (TCS and AJR,
submitted). Tight junctions are apical cell-cell junctions
found in epithelia that establish a barrier to the extracellu-
lar environment and a border for apical-basolateral polar-
ity. While hESCs grow in colonies that are highly
reminiscent of epithelia, and have been shown to be cou-
pled by gap junctions [40], the formation of tight junction
complexes has not been described. hESCs expressed the
ZO1 and occludin tight junction proteins along cell bor-
ders as expected in polarized epithelia. The distribution of
ZO1 expression changed dramatically as hESCs prolifer-
ated in culture. When tight junction complexes were dis-
rupted by disaggreagation to single cells, only a subset of
cells showed ZO1 staining 4 days after plating (Fig. 5).
Continued proliferation to a confluent monolayer on day
7 was accompanied by widespread expression of ZO1,
suggesting the formation of a general tight junction bar-
rier. These cultures were undifferentiated and retained
uniform expression of Oct4 protein (not shown). ERBB2
and 3 are members of the epidermal growth factor (EGF)-
receptor family, which regulate epithelial proliferation via
EGF-family ligands. ERBB2 and 3 transcripts are expressed
by hESCs [8], are known to function as a heterodimer
[41], and transmit a strong proliferative signal for hESCs
by Heregulin 1β (an EGF-family ligand) (TCS and AJR,
submitted). Immunofluorescence revealed general cell
surface expression of ERBB2 on hESCs. Conversely,
ERBB3 was highly localized to a concentrated area, and
observed in cells that also expressed ZO1. Epithelial cells
are known to localize ERBB receptors to the basolateral
side of tight junctions, which serves to functionally sepa-
rate receptors from ligands [42,43]. This is a basic epithe-BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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Table 2: Signal pathways that may be active in hESCs
Name Protein mRNA
TGF β Stat1 ++++ ++
PAI-1/SERPINE1 +++ -
Smad2/3 ++ ++
Jun ++ +
Smad4/DPC4 + ++
Endoglin + -
Wnt CtBP2 ++++ +++
PP2A Catalytic alpha/PPP2CA ++++ +++
EBP50/SLC9A3R1 ++++ ++
beta-Catenin/Ctnnb1 +++ +
Cyclin D3/CCND3 ++ ++
GSK-3 beta ++ ++
Jun ++ +
Casein Kinase II alpha/CSNK2A1 ++ ++
Jak-Stat Stat1 ++++ ++
Crk +++ +
Stat3/2 +++ ++
Stat6 +++ ++
PTP1B +++ ++
JAK1 ++ -
Glucocorticoid R/NR3C1 ++ -
Thrombin Receptor/PAR1/F2R ++ +
SHPS-1/PTPNS1 ++ ++
MCM5 ++ +++
Smad2/3 ++ ++
Tyk2 ++ ++
Jun ++ +
Bcl-x/BCL2L1 ++ ++
Smad4/DPC4 + ++
Stat5A + +
GPCR B2 Bradykinin Receptor/BDKRB2 ++++ -
Neurotensin Receptor 3/SORT1 +++ -
Endopeptidase 3.4.24.16/NLN ++ ++
IP3R-3 ++ ++
SHC + +++
Gap Junction Cdk1/Cdc2 ++++ ++
GRB2 ++++ ++
MEK1/MAP2K1 ++++ ++
PKA C ++ -
PKA RI alpha ++ -
PKC alpha ++ -
C-Raf/RAF1 ++ ++
ZO-1/TJP1 ++ +++
Connexin-43/GJA1 ++ ++
IGF PKC iota ++++ ++
MEK1/MAP2K1 ++++ ++
Rsk/RPS6KA1 ++++ +
GRB2 ++++ ++
MEK2/MAP2K2 +++ +++
PI3Kinase/PIK3R1 +++ ++
pan ERK/MAPK1 +++ ++
Crk +++ +
eIF-4E +++ ++
ShcC +++ -BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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PAI-1/SERPINE1 +++ -
C-Raf ++ ++
SHC ++ +++
PKC beta/PRKCB1 ++ ++
NCK ++ ++
PKB alpha/Akt ++ +
GSK-3 beta ++ ++
Ercc-1 ++ ++
Fatty Acid Synthase/FASN ++ +++
Jun ++ +
RAFT1/FRAP ++ ++
PTP1D/SHP2/PTPN11 ++ ++
SCAMP1 ++ ++
Bcl-x/BCL2L1 ++ ++
p70s6k/RPS6KB1 + -
PI3-Kinase p170/PIK3C2A + +
PTP1B/PTPN1 + ++
Dok1/p62dok + ++
PI3-Kinase p110 alpha/PIK3CA + -
ERBB EphA4/Sek ++++ -
ShcC/SHC3 +++ -
c-erb-B2/ERBB2 ++ ++
C-Raf/RAF1 ++ ++
SHC/SHC1 ++ +++
GDNF I kappa B epsilon/NFKBIE ++++ ++
GRB2 ++++ ++
MEK2 +++ +++
NCK +++ ++
C-Raf ++ ++
Ras-GAP/RASA1 ++ ++
SHC ++ +++
GDNFR-alpha/Gfra1 ++ -
Jun ++ +
IKK beta ++ ++
pan-JNK/SAPK1/MAPK10 ++ +
NBS1/ARTN + +
Dok1/p62dok + ++
Tight Junction PTEN ++++ ++
PP2A Catalytic alpha ++++ +++
PKC iota ++++ ++
Sec8/SEC8L1 +++ ++
beta-Catenin/CTNNB1 +++ +
CDC42 +++ ++
AF6/MLLT4 +++ ++
PKC alpha ++ -
Yes ++ ++
Rho/ARHA ++ +++
ZO-1/TJP1 ++ +++
CASK ++ +
Symplekin/SYMPK ++ -
Ras/NRAS ++ ++
Casein Kinase II alpha/CSNK2A1 ++ ++
VAP33/VAPA ++ +
alpha-Catenin/Ctnna1 + ++
MAPK pan ERK ++++ ++
MEK1 ++++ ++
Rsk ++++ ++
ERK2 ++++ ++
Table 2: Signal pathways that may be active in hESCs (Continued)BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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MEK2/Map2k2 +++ +++
MST3/STK25 +++ +++
ERK1 +++ ++
CDC42 +++ ++
C-Raf ++ ++
p38 alpha/SAPK2a ++ -
G3BP ++ +++
TFII-I/GTF2IRD1 ++ ++
MST1/STK4 ++ ++
MKP2/Dusp4 ++ ++
Ras ++ ++
Phospho-p38MAPK (T180/Y182) ++ +
pan-JNK/SAPK1 ++ +
Inhibitor2/PPP1R2 ++ ++
ABP-280 ++ ++++
14-3-3 epsilon/YWHAE ++ ++
MAPKAPK-5 + ++
TAO1 + *
PBK + ++
MKK3b/Map2k3 + +
Protein expression level: > 10,000: ++++; 5,000–10,000: +++; 1,000–5,000:++; 100–1,000: + mRNA gene expression level: > 5,000:++++; 1,000–
5,000: +++; 100–1,000: ++; 30–100: +
*: not included in the gene expression array
Table 2: Signal pathways that may be active in hESCs (Continued)
lial wound healing mechanism, whereby disruption of the
tight junction barrier by injury immediately exposes
receptors to extracelluar ligands [43]. These staining pat-
terns are also suggestive of basolateral sorting of ERBB3 in
hESCs. The pathways and complexes identified by these
analyses lay a framework for future functional analyses of
signaling networks in hESCs.
Discussion
Attempts to harness the potential of hESCs for models of
human embryogenesis and cell therapy applications will
be greatly enhanced by a detailed understanding of their
molecular characteristics. This includes definition of the
transcripts, splice variants, and protein isoforms expressed
by these cells. Post-translational modifications such as
phosphorylation and glycosylation, and the receptors and
signaling pathways active in the pluripotent state, or dur-
ing early differentiation, also need to be determined. This
should also be complemented by an understanding of
epigenetic characteristics of pluripotency, including meth-
ylation, imprinting and chromatin conformation. Such a
comprehensive definition of the molecular state of hESCs
will enable more accurate prediction and testing of the
conditions used for growth and differentiation of hESCs,
by precise genetic modification or application of specific
growth factor cocktails and reagents. For example, a scala-
ble, fully defined and GMP-certified culture system will
need to be developed for the eventual development of
hESC-based cellular therapies. Progress has been made in
defining growth factor conditions that support self-
renewal [44-46], and hESC lines have been isolated in the
absence of mouse embryonic fibroblasts and in animal
protein free culture conditions [47,48]. A more refined
understanding of the biology of hESCs has contributed
the development of a defined medium utilizing ligands
for IGF1R and ERBB2/3 receptors to promote in self-
renewal (TCS and AJR, submitted).
We and others have performed transcriptional analyses of
hESCs, using cDNA and oligonucleotide microarrays,
SAGE, MPSS and EST enumeration. These techniques
have enabled the collation and comparison of transcrip-
tional profiles from multiple hESC lines and their differ-
entiated derivatives and have highlighted an expanded set
of hESC specific markers and signaling pathways that may
regulate self-renewal or differentiation. Using pathway
analysis we were also able to identify key pathways that
are active in ESCs (reviewed in [16]). While these efforts
have been highly valuable in defining the transcriptional
profile of undifferentiated hESCs, they are only predictive
of translation and do not shed light on post-translational
events in this unique cell type. These processes may also
be highly regulated, which could contribute significantly
to the overall conversion of genetic information to actual
protein function.
We report here a proteomic analysis of pluripotent hESCs
by using two large-scale western blotting systems and
highlight post-translational events in undifferentiated
hESCs. The expression of 545 bands was detected, poten-
tially representing 529 proteins, or their migratory iso-
forms. In addition, one hundred and forty phospho-
specific antibodies were used to identify 85 different
phosphorylated sites, on 76 proteins in these cells. The
detected proteins were annotated into functional classes
representing diverse cellular processes. For example, mul-BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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tiple proteins were detected that have been suggested to
regulate the pluirpotent state in mouse ESCs or hESCs.
Defining the interplay of these multiple signaling path-
ways will be critical in understanding the self-renewal ver-
sus differentiation decisions of hESCs. Therefore, our data
provide a powerful framework for the functional analysis
of specific proteins, protein classes, or molecular path-
ways. In particular, the availability of antibodies for can-
didate proteins is a major benefit of this approach
compared to 2D-gel or HPLC-MS/MS based proteomics.
Although these western blotting approaches are currently
more limited in scope than most large-scale cDNA based
assays, detecting up to 1000 proteins compared to tens of
thousands of transcripts, they have the potential to high-
light translational events and post-translational modifica-
tions. By comparison, SAGE and MPSS are limited to
detecting short sequence "tags" adjacent to the poly-A tail
of transcripts, and may not distinguish splice variants with
the same 3' exon. We detected 42 proteins with multiple
closely migrating bands (Fig. 3C), suggestive of closely
related isoforms or post-translational modifications such
as phosphorylation. These focused proteomic approaches
are therefore likely to be highly complimentary to tran-
scriptional analyses in investigating the functional expres-
sion of the genome in hESCs and during cellular
differentiation.
One potential issue with this approach is that multiple
antibodies are included in each lane, which could possi-
bly lead to misidentification of bands. To demonstrate
that identified proteins were expressed in hESCs, the same
antibodies used in the PowerBlot assay were used to con-
firm expression of 10 representative proteins by immun-
ofluorescence (Fig. 4). Furthermore, 13 proteins were
detected with multiple different antibodies, and 35 pro-
teins (Table 1) were detected in both the PowerBlot and
Kinexus assays. This provided internal, or independent,
confirmation of expression of these proteins. Other stud-
ies have also demonstrated the expression of several of the
proteins we detected in hESCs. These include Oct4, a key
marker of the pluripotent state, Connexin 43 and GSK3β,
confirming the reliability of large-scale western blotting.
Finally, several proteins detected by our assays were also
detected in hESCs by MS approaches including Karyo-
pherin α [19].
Additionally, the PowerBlot assay was performed in
duplicate, and was shown to be highly reproducible. This
suggested that this approach should be informative when
Tight junction proteins and ERBB2/3 expression in hESCs Figure 5
Tight junction proteins and ERBB2/3 expression in hESCs. BG01 hESCs were disaggregated to single cells using 
accutase [52] and cultured in defined conditions. (A) ZO1 expression four and (B) seven days after plating, indicating progres-
sive tight junction formation. (C) Occludin expression 5 days after plating. (D) General cell surface expression of ERBB2, in the 
same field of view as (A). (E) Localized expression of ERBB3, in the same field of view as (B). (F) Higher magnification of ERBB3 
localization in ZO1 expressing BG01 cells, 5 days after plating. Nuclei were stained with DAPI.BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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comparing hESCs to their differentiated derivatives. Two
candidate proteins, TNIK and p130 Cas, were downregu-
lated, or exhibited altered localization upon spontaneous
differentiation of hESCs, respectively. This indicated that
they were novel markers of undifferentiated cells and mol-
ecules that could be functionally involved with self-
renewal.
It is impossible in an initial manuscript to analyze and rig-
orously test all the predictions that could be made from
comparing transcriptional and proteomic data sets. How-
ever, we did examine key features to illustrate the power
of this methodology. Potential new markers for hESCs
were identified, the expression and activation of proteins
in key self-renewal pathways were confirmed, and a
diverse range of proteins were detected and expression
correlated with transcriptional analyses. In addition, we
highlighted several candidate signaling pathways that
may be relevant to self-renewal. Examination of tight
junction protein expression indicated that undifferenti-
ated hESCs could form polarized epithelia, which has also
been recently suggested by ultrastructural analyses [49].
Discrete localization of ERBB3 may also suggest basola-
teral separation of this receptor from soluble ligand. These
analyses highlight that predictions from a combination of
transcriptional and proteomic approaches will serve to
focus the investigation of hESCs in the future.
Conclusion
In summary, we generated a focused proteome of hESCs
using large-scale western blotting and sorted the detected
proteins according to function and signaling pathways.
This characterization provides important basic informa-
tion on expressed proteins, their isoforms and post-trans-
lational modifications, and tools for the continued
investigation of the underlying molecular characteristics
of hESCs. Importantly, we provide a list of tools, in the
form of commercially available antibodies, which can be
used to interrogate the function of these molecules in self-
renewal or differentiation.
Methods
Culture of human embryonic stem cells
For the PowerBlot analysis, enzymatically passaged BG01
hESCs were grown as described previously [23]. These
conditions were necessary to scale up the culture to gener-
ate the milligram amounts of protein lysate required for
this analysis. These conditions maintain cell populations
that express the appropriate markers of pluripotency and
can differentiate to representatives of all three germ layers,
but may lead to eventual accumulation of trisomies for
chromosomes 12, 17 or X [26]. For the Kinexus assays,
BG03 hESCs were maintained in MEF-conditioned
medium (MEF-CM) without the accumulation of karyo-
typic abnormalities as described previously [14,26].
hESCs were also maintained in a defined medium as indi-
cated. These conditions are described in detail elsewhere
(TCS, AJR, submitted). Briefly, the media consisted of
DMEM/F12 (Invitrogen), 2% fatty acid-free Cohn's frac-
tion V BSA (Serologicals), 1× nonessential amino acids,
50 U/ml penicillin/streptomycin, 50 μg/ml ascorbic acid,
10 μg/ml bovine transferrin, 0.1 mM β-mecaptoethanol
(all from Invitrogen), 1× Trace Elements A, B & C (Medi-
atech), 10 ng/ml hergulin1β (Peprotech), 10 ng/ml
activinA (R&D Systems), 200 ng/ml LR3-IGF1 (JRH Bio-
sciences), and 8 ng/ml FGF2 (R&D Systems). Cultures
were passaged using Collagenase IV and plated on growth
factor depleted Matrigel (BD Biosciences) diluted 1:200.
These cultures were karyotypically normal.
To partially differentiate hESC cultures for immunostain-
ing analysis, karyotypically normal BG01 cells were plated
on matrigel and grown for three days in DMEM/F12 con-
taining 10% fetal calf serum (HyClone), 1× nonessential
amino acids, 20 mM L-glutamine, 50 U/ml penicillin/
streptomycin, and 0.1 mM β-mecaptoethanol.
PowerBlot assays
BG01 hESC lysate was prepared in 10 mM Tris-HCl pH
7.4, 1 mM sodium orthovanadate and 1% SDS, and the
PowerBlot assays were performed by BD Biosciences (BD
Biosciences). Briefly, 200 μg of protein lysate was loaded
in a single, gel-wide well, on a SDS-4–15% gradient poly-
acrylamide gel. The full PowerBlot screen consisted of five
gels, which were blotted and probed with 934 antibodies,
and was performed in duplicate with the same cell lysate.
The gel dimensions were 130 × 100 × 0.5 mm, and pro-
teins were separated at 150 volts for 1.5 hours, and trans-
ferred to an Immobilon-P membrane (Millipore). The
membranes were blocked and clamped in a manifold that
created 40 lanes across each membrane. A mix of 1 to 8
mouse monoclonal primary antibodies was added to each
lane, in dilutions and combinations that had been prede-
termined to enable accurate identification of well-sepa-
rated proteins. The predicted sizes of detectable proteins
in the blots ranged from 10–540 kD, and the dilutions of
the primary antibodies ranged from 1:250 to 1:15,000.
The blots were removed from the manifolds, washed and
incubated with goat anti-mouse secondary antibody con-
jugated to the Alexa680 fluorophore (Molecular Probes).
The membranes were scanned using the Odyssey Imaging
System (LI-COR). Molecular weight standards were gener-
ated by adding a cocktail of antibodies to P190 (190 kD),
Adaptin beta (106 kD), STAT-3 (92 kD), PTP1D (72 kD),
Mek-2 (46 kD), RACK-1 (36 kD), GRB-2 (24 kD) and
Rap2 (21 kD) to lane 40 of gels A-D. Molecular standards
for gel E were generated by adding a cocktail of antibodies
to Exportin-1/CRM1 (112 kD), MCM (83 kD), Nucleop-
orin p62 (62 kD), α-tubulin (55 kD), Actin (42 kD), KNP-BMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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1/HES1 (28 kD) and NTF2 (15 kD) to lane 16, and anti-
bodies to p190 (190 kD), Hip1R (120 kD), Transportin
(101 kD), Calreticulin (60 kD), Arp3 (50 kD), eIF-6 (27
kD) and Rap2 (21 kD) to lane 17.
Bands were detected and raw signal intensity captured
automatically using the PDQuest software (Bio-Rad). To
normalize the signal intensities, the total raw quantity of
each band was divided by the average intensity value of
the molecular standards in that image and the normalized
values for the duplicate samples were averaged and
expressed as normalized intensity units (i.u.). These val-
ues represent the relative signal intensity observed for
each identified protein band, rather than relative expres-
sion levels of different proteins, due to differences in the
efficiencies of antibody binding and dilution of the pri-
mary antibodies used. Proteins were identified based on
the similarity of expected and observed band migration
profiles and bands that could not be identified were
excluded from the analysis. All identified proteins were
verified by visual inspection, and proteins exhibiting a
low signal intensity, with an averaged signal of < 1000 i.u.,
were verified by visual inspection using contrast enhance-
ment in Adobe Photoshop. Bands with > 800 i.u. could
typically be observed without additional image enhance-
ment. Microsoft Excel files were generated that contained
information on: gel number, lane number, antibody cata-
logue number (BD Biosciences), protein name, expected
size, observed size, repeat 1 i.u. value, repeat 2 i.u. value,
averaged i.u. value, antibody dilution, outline of protein
function, Entrez gene and SwissProt identification num-
bers. These tables were used to list expressed proteins
(Additional File 1).
Kinexus assays
Preparation of the BG03 cell lysate and western blotting
was performed according to published protocols [50].
Briefly, cell lysate was prepared in 20 mM MOPS pH 7.0,
2 mM EGTA, 5 mM EDTA, 30 mM sodium fluoride, 40
mM β-glycerolphosphate pH 7.2, 20 mM sodium pyro-
phosphate, 1 mM sodium orthovanadate, 1 mM PMSF, 3
mM benzamidine, 5 μM pepstatin, 10 μM leupeptin,
0.5% nonidet P-40, with the final pH adjusted to 7.2. The
Kinexus assays for protein kinases (KPKS-1.2A and B [76
antibodies]), phosphatases (KPPS-1.2 [27 antibodies])
and phosporylated sites in cell signaling molecules (KPSS-
3.1 [37 antibodies]) were performed by Kinexus. The Bio-
Rad Mini-PROTEAN 3 electrophoresis system was used to
separate proteins by SDS-PAGE. For each assay, 250 μg of
cell lysate was loaded in a single well spanning the width
of the stacking gel, then separated through a 12.5% SDS-
Polyacrylamide gel and transferred to a PVDF membrane.
A 20-lane manifold was placed over the membrane and a
different mixture of up to 3 primary antibodies was added
to each well. The combinations of primary antibodies had
been predetermined to detect well-separated proteins,
avoiding crossreaction to different proteins that co-
migrate. The primary antibodies were rabbit and goat pol-
yclonal, and mouse monoclonal antibodies, diluted
1:1000. After incubation with the primary antibodies, the
membranes were removed from the manifolds, washed
and incubated with a mix of the appropriate secondary
antibodies. The secondary antibodies were donkey anti-
rabbit (at 1:5000), sheep anti-mouse (at 1:10,000) and
bovine anti-goat (at 1:10,000), all conjugated with horse
radish peroxidase. The membranes were washed and
immunoreactive bands detected by enhanced chemilumi-
nescence (Amersham-Pharmacia) using a FluorS Max
Multi-imager (Bio-Rad). Prestained size markers (201.5,
156.8, 106, 79.7, 48.4, 37.8, 23.3, and 18.2 kD) and pre-
determined human-specific protein migration profiles
were used to accurately identify proteins using the Kin-
exus immuno-reactivity identification system (IRIS) soft-
ware. Detected proteins were verified by visual inspection.
Immunocytochemistry
Immunocytochemistry and staining procedures were as
described previously [51]. Briefly, cells were fixed with 4%
paraformaldehyde for half an hour, blocked in blocking
buffer (5% goat serum, 1% BSA, 0.1% Triton X-100) for 1
hour followed by incubation with the primary antibody at
4°C overnight. Appropriately coupled secondary antibod-
ies (Molecular Probes) were used for single and double
labeling. All secondary antibodies were tested for cross
reactivity and non-specific immunoreactivity. The follow-
ing antibodies were used: ABP-280 (1:250, BD Bio-
sciences 610798), CtBP1 (1:1000, BD Biosciences
612042), CtBP2 (1:1000, BD Biosciences 612044), GS-28
(1:2000, BD Biosciences 611184), HDJ-2 (1:100, BD Bio-
sciences 611872), L-Caldesmon (1:2000, BD Biosciences
610660), Rabaptin-5 (1:500, BD Biosciences 611080),
phospho-p130 Cas (Tyr165) (1:50, Cell Signaling Tech-
nology 4015), phospho-Ras-GAP (pY460) (1:250, BD
Biosciences 612736), Ras-GAP (1:250, BD Biosciences
610043), Shc-C (1:1000, BD Biosciences 610642), Oct-4
(Santa Cruz biotechnology, 1:200 SC-8628), TNIK
(1:100, BD Biosciences, 612250), p130 Cas (1:100, BD
Biosciences, 610272), ERBB2 (1:100, Lab Vision,
9G6.10), ERBB3 (1:100, R&D Systems, MAB348), ZO1
(1:100, Invitrogen, 61–7300), or Occludin (1:100, Invit-
rogen, 71–1500). Hoechst (Invitrogen) or DAPI (Sigma)
were used to identify nuclei, and Triton X-100 was omit-
ted when staining for extracellular antigens (ZO1, occlu-
din, ERBB2/3). Images were captured on an Olympus or
Nikon fluorescence microscope.
lllumina data and comparison to proteomic database
Expression levels of proteins detected by the PowerBlot
assay were compared to our previous published database
of multiple hESC lines examined using the Illumina beadBMC Genomics 2007, 8:478 http://www.biomedcentral.com/1471-2164/8/478
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array platform (Liu et al., 2006). Averaged transcript
expression signals from the BG01, BG02 and BG03 cell
lines were converted to a +/- format, based on the follow-
ing criteria: A mean transcript detection level of > 5,000
was designated as ++++; 1,000–5,000 as +++; 100–1,000
as ++; 30–100 as +; and signals < 30 was represented as -.
In parallel, the protein expression levels were converted to
a +/- format based on these criteria: i.u. > 10,000 as ++++;
5,000–10,000 as +++; 1,000–5,000 as ++; 100–1,000 as +.
In addition, genes were categorized into the same func-
tional/signaling pathways as per the western blot data-
base.
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